Protein kinase Cβ is required for lupus development in sle mice

Arthritis and Rheumatism

Volumn 65, Issue 4, 2013, Pages 1022-1031

  Oleksyn, David ^a   Pulvino, Mary ^a   Zhao, Jiyong ^a   Misra, Ravi ^a   Vosoughi, Aram ^a   Jenks, Scott ^a   Tipton, Christopher ^a   Lund, Frances ^a   Schwartz, George ^a   Goldman, Bruce ^a   Mohan, Chandra ^b   Mehta, Kamal ^c   Mehta, Madhu ^c   Leitgets, Michael ^d   Sanz, Ignacio ^a   Chen, Luojing ^e  

^a EMORY UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF OSLO   (Norway)

^e UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; ENZASTAURIN; PROTEIN KINASE C BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CELL SURVIVAL; CLONAL ANERGY; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE SUBPOPULATION; MOUSE; NONHUMAN; PHENOTYPE; PLASMA CELL; PRIORITY JOURNAL; PROTEINURIA; SPLEEN SIZE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION;

ANIMALS; APOPTOSIS; B-LYMPHOCYTES; CELL SURVIVAL; DISEASE MODELS, ANIMAL; HUMANS; INDOLES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, CONGENIC; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS;

EID: 84875728626     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.37825     Document Type: Article

References (50)

1. Sanz I, Lee FE,. B cells as therapeutic targets in SLE. Nat Rev Rheumatol 2010; 6: 326-37.
2. Looney RJ, Anolik J, Sanz I,. A perspective on B-cell-targeting therapy for SLE. Mod Rheumatol 2010; 20: 1-10.
3. Doreau A, Belot A, Bastid J, Riche B, Trescol-Biemont MC, Ranchin B, et al. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol 2009; 10: 778-85.
4. Stadanlick JE, Kaileh M, Karnell FG, Scholz JL, Miller JP, Quinn WJ III, et al. Tonic B cell antigen receptor signals supply an NF-κB substrate for prosurvival BLyS signaling. Nat Immunol 2008; 9: 1379-87.
5. Cancro MP,. Signalling crosstalk in B cells: managing worth and need. Nat Rev Immunol 2009; 9: 657-61.
6. Goodnow CC,. Multistep pathogenesis of autoimmune disease. Cell 2007; 130: 25-35.
7. Shlomchik MJ,. Sites and stages of autoreactive B cell activation and regulation. Immunity 2008; 28: 18-28.
8. Pillai S, Mattoo H, Cariappa A,. B cells and autoimmunity. Curr Opin Immunol 2011; 23: 721-31.
9. Meffre E, Davis E, Schiff C, Cunningham-Rundles C, Ivashkiv LB, Staudt LM, et al. Circulating human B cells that express surrogate light chains and edited receptors. Nat Immunol 2000; 1: 207-13.
10. Fang W, Weintraub BC, Dunlap B, Garside P, Pape KA, Jenkins MK, et al. Self-reactive B lymphocytes overexpressing Bcl-xL escape negative selection and are tolerized by clonal anergy and receptor editing. Immunity 1998; 9: 35-45.
11. Guo B, Su TT, Rawlings DJ,. Protein kinase C family functions in B-cell activation. Curr Opin Immunol 2004; 16: 367-73.
12. Saijo K, Mecklenbrauker I, Schmedt C, Tarakhovsky A,. B cell immunity regulated by the protein kinase C family. Ann N Y Acad Sci 2003; 987: 125-34.
13. Leitges M, Schmedt C, Guinamard R, Davoust J, Schaal S, Stabel S, et al. Immunodeficiency in protein kinase cβ-deficient mice. Science 1996; 273: 788-91.
14. Su TT, Guo B, Kawakami Y, Sommer K, Chae K, Humphries LA, et al. PKC-β controls IκB kinase lipid raft recruitment and activation in response to BCR signaling. Nat Immunol 2002; 3: 780-6.
15. Saijo K, Mecklenbrauker I, Santana A, Leitger M, Schmedt C, Tarakhovsky A,. Protein kinase Cβ controls nuclear factor κB activation in B cells through selective regulation of the IκB kinase α. J Exp Med 2002; 195: 1647-52.
16. Shinohara H, Kurosaki T,. Comprehending the complex connection between PKCβ, TAK1, and IKK in BCR signaling. Immunol Rev 2009; 232: 300-18.
17. Stadanlick JE, Cancro MP,. BAFF and the plasticity of peripheral B cell tolerance. Curr Opin Immunol 2008; 20: 158-61.
18. Liu Z, Davidson A,. BAFF and selection of autoreactive B cells. Trends Immunol 2011; 32: 388-94.
19. Patke A, Mecklenbrauker I, Erdjument-Bromage H, Tempst P, Tarakhovsky A,. BAFF controls B cell metabolic fitness through a PKCβ- and Akt-dependent mechanism. J Exp Med 2006; 203: 2551-62.
20. Mohan C, Alas E, Morel L, Yang P, Wakeland EK,. Genetic dissection of SLE pathogenesis: Sle1 on murine chromosome 1 leads to a selective loss of tolerance to H2A/H2B/DNA subnucleosomes. J Clin Invest 1998; 101: 1362-72.
21. Morel L, Mohan C, Yu Y, Croker BP, Tian N, Deng A, et al. Functional dissection of systemic lupus erythematosus using congenic mouse strains. J Immunol 1997; 158: 6019-28.
22. Wu T, Qin X, Kurepa Z, Kumar KR, Liu K, Kanta H, et al. Shared signaling networks active in B cells isolated from genetically distinct mouse models of lupus. J Clin Invest 2007; 117: 2186-96.
23. Bansode RR, Huang W, Roy SK, Mehta M, Mehta KD,. Protein kinase C deficiency increases fatty acid oxidation and reduces fat storage. J Biol Chem 2008; 283: 231-6.
24. Morel L, Yu Y, Blenman KR, Caldwell RA, Wakeland EK,. Production of congenic mouse strains carrying genomic intervals containing SLE-susceptibility genes derived from the SLE-prone NZM2410 strain. Mamm Genome 1996; 7: 335-9.
25. Cariappa A, Chen L, Haider K, Tang M, Nebelitskiy E, Moran ST, et al. A catalytically inactive form of protein kinase C- associated kinase/receptor interacting protein 4, a protein kinase C β-associated kinase that mediates NF-κB activation, interferes with early B cell development. J Immunol 2003; 171: 1875-80.
26. Quach TD, Manjarrez-Orduno N, Adlowitz DG, Silver L, Yang H, Wei C, et al. Anergic responses characterize a large fraction of human autoreactive naive B cells expressing low levels of surface IgM. J Immunol 2011; 186: 4640-8.
27. Mohan C, Yu Y, Morel L, Yang P, Wakeland EK,. Genetic dissection of Sle pathogenesis: Sle3 on murine chromosome 7 impacts T cell activation, differentiation, and cell death. J Immunol 1999; 162: 6492-502.
28. Ichikawa HT, Conley T, Muchamuel T, Jiang J, Lee S, Owen T, et al. Novel proteasome inhibitors have a beneficial effect in murine lupus via the dual inhibition of type I interferon and autoantibody-secreting cells. Arthritis Rheum 2012; 64: 493-503.
29. Mohan C, Morel L, Yang P, Watanabe H, Croker B, Gilkeson G, et al. Genetic dissection of lupus pathogenesis: a recipe for nephrophilic autoantibodies. J Clin Invest 1999; 103: 1685-95.
30. Zhu J, Mohan C,. SLE 1, 2, 3. genetic dissection of lupus. Adv Exp Med Biol 2007; 601: 85-95.
31. Haraldsson MK, dela Paz NG, Kuan JG, Gilkeson GS, Theofilopoulos AN, Kono DH,. Autoimmune alterations induced by the New Zealand Black Lbw2 locus in BWF1 mice. J Immunol 2005; 174: 5065-73.
32. Morel L, Croker BP, Blenman KR, Mohan C, Huang G, Gilkeson G, et al. Genetic reconstitution of systemic lupus erythematosus immunopathology with polycongenic murine strains. Proc Natl Acad Sci U S A 2000; 97: 6670-5.
33. Duan B, Morel L,. Role of B-1a cells in autoimmunity. Autoimmun Rev 2006; 5: 403-8.
34. + human B1 cell subpopulation stimulates T cells and is expanded in lupus. J Exp Med 2011; 208: 2591-8.
35. Venkataraman C, Chen XC, Na S, Lee L, Neote K, Tan SL,. Selective role of PKCβ enzymatic function in regulating cell survival mediated by B cell antigen receptor cross-linking. Immunol Lett 2006; 105: 83-9.
36. Monroe JG,. Molecular mechanisms regulating B cell responsiveness and tolerance. Transplantation 2005; 79 Suppl: S12-3.
37. Carducci MA, Musib L, Kies MS, Pili R, Truong M, Brahmer JR, et al. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase Cβ inhibitor, in patients with advanced cancer. J Clin Oncol 2006; 24: 4092-9.
38. Cappione A III, Anolik JH, Pugh-Bernard A, Barnard J, Dutcher P, Silverman G, et al. Germinal center exclusion of autoreactive B cells is defective in human systemic lupus erythematosus. J Clin Invest 2005; 115: 3205-16.
39. Cambier JC, Getahun A,. B cell activation versus anergy: the antigen receptor as a molecular switch. Immunol Lett 2010; 128: 6-7.
40. Anolik JH,. B cell biology and dysfunction in SLE. Bull NYU Hosp Jt Dis 2007; 65: 182-6.
41. Serreze DV, Fleming SA, Chapman HD, Richard SD, Leiter EH, Tisch RM,. B lymphocytes are critical antigen-presenting cells for the initiation of T cell-mediated autoimmune diabetes in nonobese diabetic mice. J Immunol 1998; 161: 3912-8.
42. Liang B, Gee RJ, Kashgarian MJ, Sharpe AH, Mamula MJ,. B7 costimulation in the development of lupus: autoimmunity arises either in the absence of B7.1/B7.2 or in the presence of anti-b7.1/B7.2 blocking antibodies. J Immunol 1999; 163: 2322-9.
43. Pao LI, Lam KP, Henderson JM, Kutok JL, Alimzhanov M, Nitschke L, et al. B cell-specific deletion of protein-tyrosine phosphatase Shp1 promotes B-1a cell development and causes systemic autoimmunity. Immunity 2007; 27: 35-48.
44. Murakami M, Yoshioka H, Shirai T, Tsubata T, Honjo T,. Prevention of autoimmune symptoms in autoimmune-prone mice by elimination of B-1 cells. Int Immunol 1995; 7: 877-82.
45. Hagiwara E, Gourley MF, Lee S, Klinman DK,. Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10:interferon-γ-secreting cells in the peripheral blood. Arthritis Rheum 1996; 39: 379-85.
46. Mohan C, Morel L, Yang P, Wakeland EK,. Accumulation of splenic B1a cells with potent antigen-presenting capability in NZM2410 lupus-prone mice. Arthritis Rheum 1998; 41: 1652-62.
47. Hammerman PS, Fox CJ, Thompson CB,. Beginnings of a signal-transduction pathway for bioenergetic control of cell survival. Trends Biochem Sci 2004; 29: 586-92.
48. Brink R,. Regulation of B cell self-tolerance by BAFF. Semin Immunol 2006; 18: 276-83.
49. Sanz I,. Connective tissue diseases: targeting B cells in SLE: good news at last ! Nat Rev Rheumatol 2011; 7: 255-6.
50. Stohl W,. Targeting B lymphocyte stimulator in systemic lupus erythematosus and other autoimmune rheumatic disorders. Expert Opin Ther Targets 2004; 8: 177-89.